The outcome of severe Guillain-Barré syndrome after robotic or conventional rehabilitation also depends on the triggering agent and the electrophysiological subtype
Abstract
Dear Editor,
We read with interest the article by Tramonti et al. about a 54-year-old man with severe Guillain-Barré Syndrome (GBS) following a flu-like infection in April 2022, which required long-term intubation and mechanical ventilation.1 Despite immediate treatment with steroids, Intravenous Immunoglobulins (IVIG), and Plasma Exchange (PE), the patient was discharged to a rehabilitation facility after 9 months with severe quadruparesis and weakness of the axial, respiratory, and pharyngeal muscles.1 After intensive rehabilitation with conventional and robot-assisted approaches, the patient's condition improved significantly after another two months.1 The study is noteworthy, but some points require discussion. [...]
References
- 1. Tramonti C, Gnetti B, Gemignani P, et al. Is a multidimensional robotic rehabilitation approach feasible in Guillain-Barrè syndrome? Report from a clinical case. Eur J Transl Myol 2025;35:12758. DOI: https://doi.org/10.4081/ejtm.2025.12758
- 2. Kilinc D, van de Pasch S, Doets AY, et al. Guillain-Barré syndrome after SARS-CoV-2 infection. Eur J Neurol 2020;27:1757-8. DOI: https://doi.org/10.1111/ene.14398
- 3. Finsterer J. Triggers of Guillain-Barré Syndrome: Campylobacter jejuni Predominates. Int J Mol Sci 2022;23:14222. DOI: https://doi.org/10.3390/ijms232214222
- 4. Hughes RA, van Der Meché FG. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev 2000;3:CD001446. Update in: Cochrane Database Syst Rev 2006;2:CD001446. DOI: https://doi.org/10.1002/14651858.CD001446
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.